Genmab A/S
GMAB
View Detailed Chart
28.660USD
-0.180-0.62%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
17.65BMarket Cap
11.91P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.62%
5 Days
+0.17%
1 Month
-10.02%
6 Months
+48.04%
Year to Date
+37.33%
1 Year
+24.18%
View Detailed Chart
TradingKey Stock Score of Genmab A/S
Currency: USD Updated: 2025-11-07Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Genmab A/S's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Buy
Current Rating
35.911
Target Price
+25.30%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Genmab A/S Highlights
StrengthsRisks
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 51.10% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.12B.
Fairly Valued
The company’s latest PE is 2.82, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 64.81M shares, decreasing 19.49% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 2.77M shares of this stock.
Genmab A/S News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Genmab A/S Info
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Ticker SymbolGMAB
CompanyGenmab A/S
CEODr. Jan G.J. Van De Winkel, Ph.D.
Websitehttps://www.genmab.com/
Related Instruments
-1.43%
-0.22%
+0.06%
+0.97%
-0.17%
+0.59%
+1.46%
-1.78%
-3.70%
+0.06%
+0.34%
-0.77%
-1.63%
+0.16%
-1.00%
+0.58%
0.00%
+1.65%
+0.50%
+0.57%Popular Symbols
